Table 1.
Molecular characteristics
| No | Age at initial diagnosis | Histological diagnosis | Contrast enhancement | Fusion | TERT promoter | Chr + 7/− 10 | WHO 2021 | Hierarchical clustering | t-SNE cluster | MC v11b4 | CS v11 | MC v12.5 | CS v12.5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #01 | 56 | GB | Present | FGFR3(ex18)::TACC3(int6) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_RTK2 | 0.94 |
| #02 | 44 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_RTK2 | 0.57 |
| #03 | 65 | LGG | Present | FGFR3(ex17)::TACC3(ex4) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_MES_TYP | 0.65 |
| #04 | 63 | GB | Present | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 2 | GB | Glioblastoma IDH wildtype | 0.99 | GB_MES_TYP | 0.97 |
| #05 | 58 | GB | Present | FGFR3(ex17)::TACC3(ex8) | Mutated | Present | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.99 | GG | 0.36 |
| #06 | 68 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.71 | GB_MES_TYP | 0.81 |
| #07 | 56 | LGG | No | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.90 | GG | 0.54 |
| #08 | 60 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.85 | GB_MES_TYP | 0.89 |
| #09 | 77 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 3 | GB | Glioblastoma IDH wildtype | 0.67 | GB_MES_TYP | 0.84 |
| #10 | 45 | LGG | NA | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 3 | GB | plexus tumor | 0.39 | GB_MES_TYP | 0.31 |
| #11 | 41 | GB | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Present | GB IDH-WT | Group 4 | GB | NM | < 0.3 | GG | 0.23 |
| #12 | 24 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 4 | GB | LGG, GG | 0.13 | GG | 0.41 |
| #12bis | NA | LGG | NA | FGFR3(ex17)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 4 | GB | Glioblastoma IDH wildtype | 0.74 | GG | 0.61 |
| #13 | 4 | LGG | Present | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 3 | GG | NM | < 0.3 | IHG | 0.26 |
| #14 | 12 | LGG | No | FGFR3(ex17)::TACC3(ex13) | Wildtype | Absent | PLGG | Group 3 | GG | LGG, GG | 0.99 | GG | 0.99 |
| #15 | 72 | LGG | Present | FGFR3(ex17)::TACC3(ex11) | Mutated | Absent | GB IDH-WT | Group 3 | GG | LGG, GG | 0.70 | GG | 0.99 |
| #16 | 10 | LGG | No | FGFR3(ex17)::TACC3(ex12) | Wildtype | Absent | PLGG | Group 3 | GG | LGG, GG | 0.89 | GG | 0.99 |
| #17 | 38 | LGG | No | FGFR3(ex18)::TACC3(ex10) | Mutated | Present | GB IDH-WT | Group 3 | GG | LGG, GG | 0.59 | GG | 0.98 |
| #18 | 13 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.6 | DNET | 0.77 |
| #19 | 29 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.26 | RGNT | 0.28 |
| #20 | 6 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.99 | DNET | 0.98 |
| #21bis | 29 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.56 | MYXGNT, PDGFRA-mutant (novel) | 0.57 |
| #22 | 1 | LGG | No | FGFR3(ex17)::TACC3(ex10) | Wildtype | Absent | PLGG | Group 1 | DNET | LGG, DNET | 0.48 | GG | 0.39 |
CS calibrated score, DNET dysembryoplastic neuroepithelial tumor methylation class, Ex exon, GB glioblastoma methylation class by t-SNE clustering, GB IDH-WT glioblastoma, IDH-wildtype integrated diagnosis according to 2021 World Health Organization classification, GB glioblastoma at histology, GB_MES_TYP glioblastoma mesenchymal subtype methylation class, GB_RTK2 glioblastoma RTK2 subtype methylation class, GG ganglioglioma methylation class, IHG infantile hemispheric glioma methylation class, In intron, LGG low grade glioma at histology, LGG, DNET low grade glioma dysembryoplastic neuroepithelial tumor methylation class, LGG, GG low grade glioma ganglioglioma methylation class, MC methylation class, LGG low grade glioma histology, MYXGNT, PDGFRA-mutant (novel) myxoid glioneuronal tumor PDGFRA-mutant methylation class (novel), NA not available, NM no match, LGG pediatric low grade glioma integrated diagnosis according to 2021 World Health Organization classification, RGNT rosette forming glioneuronal tumor methylation class